WILMINGTON, MASSACHUSETTS -- (MARKET WIRE) -- March 16, 2007 -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, today reported financial results for the fourth quarter and full year ended December 31, 2006.
